{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:34:58Z","timestamp":1791218098957,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.pupt.2004.08.001","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T13:53:41Z","timestamp":1097675621000},"page":"1-8","source":"Crossref","is-referenced-by-count":58,"title":["Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options"],"prefix":"10.1016","volume":"18","author":[{"given":"Duncan F.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2004.08.001_bib1","doi-asserted-by":"crossref","unstructured":"Rogers DF. Overview of airway mucus clearance. In: Rubin BK, van der Schans CP, editors. Therapy for mucus-clearance disorders: lung biology in health and disease. Lenfant C, editor. vol. 188. New York: Marcel Dekker; 2004 [in press].","DOI":"10.1201\/b14041-2"},{"key":"10.1016\/j.pupt.2004.08.001_bib2","doi-asserted-by":"crossref","first-page":"121S","DOI":"10.1378\/chest.121.5_suppl.121S","article-title":"COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity","volume":"121","author":"Mannino","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib3","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990\u20132020: global burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2004.08.001_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.02.03242002","article-title":"Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey","volume":"20","author":"Rennard","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib5","article-title":"Global initiative for chronic obstructive lung disease","year":"2001"},{"key":"10.1016\/j.pupt.2004.08.001_bib6","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.290.17.2301","article-title":"Contemporary management of chronic obstructive pulmonary disease: scientific review","volume":"290","author":"Sin","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pupt.2004.08.001_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.coph.2004.03.001","article-title":"COPD: is there light at the end of the tunnel?","volume":"4","author":"Barnes","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pupt.2004.08.001_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1517\/14656566.1.5.1007","article-title":"Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease","volume":"1","author":"Culpitt","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pupt.2004.08.001_bib9","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2165\/00003495-200363190-00002","article-title":"Therapy for COPD in the 21st Century","volume":"63","author":"Donnelly","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2004.08.001_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1517\/13543776.13.9.1345","article-title":"Antiproteases and retinoids for treatment of COPD","volume":"13","author":"Donnelly","year":"2003","journal-title":"Expert Opin Ther Patents"},{"key":"10.1016\/j.pupt.2004.08.001_bib11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1378\/chest.103.5.1390","article-title":"Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease","volume":"103","author":"Smaldone","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib12","series-title":"Textbook of respiratory medicine","first-page":"1331","article-title":"Chronic bronchitis and emphysema","author":"Snider","year":"1994"},{"key":"10.1016\/j.pupt.2004.08.001_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1164\/ajrccm\/140.2.477","article-title":"Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease","volume":"140","author":"Aikawa","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pupt.2004.08.001_bib14","first-page":"465","article-title":"Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases","volume":"117","author":"Lopez-Vidriero","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pupt.2004.08.001_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/01902148609058290","article-title":"Density gradient analysis of secretions produced in vitro by human and canine airway mucosa: identification of lipids and proteoglycans in such secretions","volume":"10","author":"Bhaskar","year":"1986","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.pupt.2004.08.001_bib16","first-page":"324","article-title":"Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy","volume":"55","author":"Rogers","year":"2000","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.pupt.2004.08.001_bib17","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1164\/ajrccm.153.5.8630597","article-title":"Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group","volume":"153","author":"Vestbo","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1183\/09031936.95.08081333","article-title":"Chronic mucus hypersecretion in COPD and death from pulmonary infection","volume":"8","author":"Prescott","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/S0140-6736(02)08788-3","article-title":"Does mucus hypersecretion matter in airway disease?","volume":"359","author":"Melton","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2004.08.001_bib20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/thx.42.11.843","article-title":"Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function","volume":"42","author":"Mullen","year":"1987","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2004.08.001_bib21","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1378\/chest.97.2_Supplement.11S","article-title":"The role of mucus in chronic obstructive pulmonary disease","volume":"97","author":"Wanner","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib22","first-page":"73","article-title":"Clinical aspects of mucociliary transport","volume":"116","author":"Wanner","year":"1977","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pupt.2004.08.001_bib23","first-page":"429","article-title":"Abnormal cilia in human bronchial epithelium","volume":"100","author":"McDowell","year":"1976","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00151829-200403030-00003","article-title":"Role of neutrophils in mucus hypersecretion in COPD and implications for therapy","volume":"3","author":"Kim","year":"2004","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1471-4914(01)01912-8","article-title":"Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease?","volume":"7","author":"MacNee","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib26","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.164.3.1546","article-title":"Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils","volume":"164","author":"Takeyama","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.pupt.2004.08.001_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1042\/bj3130431","article-title":"Mucins in airway secretions from healthy and chronic bronchitic subjects","volume":"313","author":"Davies","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.pupt.2004.08.001_bib28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1042\/bj3160967","article-title":"Respiratory mucins: identification of core proteins and glycoforms","volume":"316","author":"Thornton","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.pupt.2004.08.001_bib29","doi-asserted-by":"crossref","first-page":"286S","DOI":"10.1378\/chest.117.5_suppl_1.286S","article-title":"Bacterial infection and the pathogenesis of COPD","volume":"117","author":"Sethi","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09031936.03.00063703","article-title":"Global Strategy for the diagnosis, management and prevention of COPD: 2003 update","volume":"22","author":"Fabbri","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/13543784.11.1.15","article-title":"Mucoactive drugs for asthma and COPD: any place in therapy?","volume":"11","author":"Rogers","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pupt.2004.08.001_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/0470860790.ch16","article-title":"Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases","volume":"248","author":"Disse","year":"2002","journal-title":"Novartis Found Symp"},{"key":"10.1016\/j.pupt.2004.08.001_bib33","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1378\/chest.110.4.1048","article-title":"Treatment of mucociliary dysfunction","volume":"110","author":"Salathe","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib34","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.322.7297.1271","article-title":"Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review","volume":"322","author":"Poole","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.pupt.2004.08.001_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annhyg\/26.2.227","article-title":"Lung mucociliary function in man: interdependence of bronchial and tracheal mucus transport velocities with lung clearance in bronchial asthma and healthy subjects","volume":"26","author":"Foster","year":"1982","journal-title":"Ann Occup Hyg"},{"key":"10.1016\/j.pupt.2004.08.001_bib36","first-page":"100","article-title":"Effect of orally administered orciprenaline on tracheobronchial mucociliary clearance","volume":"69","author":"Yeates","year":"1986","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.pupt.2004.08.001_bib37","first-page":"119","article-title":"Tracheobronchial clearance in bronchial asthma: response to beta-adrenoceptor stimulation","volume":"57","author":"Mossberg","year":"1976","journal-title":"Scand J Respir Dis"},{"key":"10.1016\/j.pupt.2004.08.001_bib38","first-page":"281","article-title":"Tracheobronchial clearance and beta-adrenoceptor stimulation in patients with chronic bronchitis","volume":"57","author":"Mossberg","year":"1976","journal-title":"Scand J Respir Dis"},{"key":"10.1016\/j.pupt.2004.08.001_bib39","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1067\/mai.2002.129704","article-title":"Effect of beta-adrenergic agonists on mucociliary clearance","volume":"110","author":"Bennett","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pupt.2004.08.001_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0952-0600(92)90068-R","article-title":"The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro","volume":"5","author":"Devalia","year":"1992","journal-title":"Pulm Pharmacol"},{"key":"10.1016\/j.pupt.2004.08.001_bib41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1152\/jappl.1989.66.3.1035","article-title":"Effect of cAMP on ciliary function in rabbit tracheal epithelial cells","volume":"66","author":"Tamaoki","year":"1989","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pupt.2004.08.001_bib42","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1067\/mai.2002.129412","article-title":"Effects of beta-agonists on airway epithelial cells","volume":"110","author":"Salathe","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pupt.2004.08.001_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/cs0630023","article-title":"Sympathomimetic drugs stimulate the output of secretory glycoproteins from human bronchi in vitro","volume":"63","author":"Phipps","year":"1982","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pupt.2004.08.001_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0002-9343(85)90082-8","article-title":"Effects of methylxanthines on airway mucociliary function","volume":"79","author":"Wanner","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/jam.1990.3.187","article-title":"Effect of bronchodilators on mucociliary clearance in normal adults","volume":"3","author":"Perry","year":"1990","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib48","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1183\/09031936.02.00240902","article-title":"Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial","volume":"19","author":"Aalbers","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib49","first-page":"A636","article-title":"Salmeterol speeds mucociliary transport in healthy subjects","volume":"159","author":"Chambers","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/rmed.2003.1498","article-title":"Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma","volume":"97","author":"Hasani","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib51","first-page":"503","article-title":"The influence of a new beta agonist: formoterol on mucociliary function","volume":"9","author":"Melloni","year":"1992","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.pupt.2004.08.001_bib52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1164\/ajrccm.155.1.9001332","article-title":"Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa","volume":"155","author":"Dowling","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1183\/09031936.98.11010086","article-title":"Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro","volume":"11","author":"Dowling","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1165\/rcmb.2003-0056OC","article-title":"Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist","volume":"30","author":"Coraux","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pupt.2004.08.001_bib55","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1183\/09031936.02.00542001","article-title":"Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study","volume":"20","author":"Jeffery","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/01902148709069594","article-title":"An ultrastructural study of the response of hamster bronchial epithelium to human neutrophil elastase","volume":"13","author":"Christensen","year":"1987","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.pupt.2004.08.001_bib57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.120.1.258","article-title":"Alternative mechanisms for long-acting \u03b22-adrenergic agonists in COPD","volume":"120","author":"Johnson","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib58","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1378\/chest.117.6.1633","article-title":"Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation?","volume":"117","author":"Balbi","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2004.08.001_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000029466","article-title":"Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease","volume":"67","author":"Yildiz","year":"2000","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2004.08.001_bib60","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1164\/rccm.2105025","article-title":"The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study","volume":"165","author":"Hattotuwa","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib61","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.pupt.2004.08.001_bib62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2004.08.001_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib64","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1034\/j.1399-3003.1999.14b21.x","article-title":"Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro","volume":"14","author":"Dowling","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib65","first-page":"L484","article-title":"Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells","volume":"271","author":"Kai","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pupt.2004.08.001_bib66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1471-4892(02)00146-7","article-title":"Pharmacological regulation of the neuronal control of airway mucus secretion","volume":"2","author":"Rogers","year":"2002","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pupt.2004.08.001_bib67","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/00039896.1974.10666572","article-title":"Increased mucociliary transport by cholinergic stimulation","volume":"29","author":"Cammer","year":"1974","journal-title":"Arch Environ Health"},{"key":"10.1016\/j.pupt.2004.08.001_bib68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0034-5687(93)90039-D","article-title":"Cholinergic and adrenergic stimulation of mucociliary transport in the rat trachea","volume":"92","author":"Gatto","year":"1993","journal-title":"Respir Physiol"},{"key":"10.1016\/j.pupt.2004.08.001_bib69","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/15287397809529682","article-title":"Effects of atropine and methacholine on deposition and clearance of inhaled particles in the donkey","volume":"4","author":"Berger","year":"1978","journal-title":"J Toxicol Environ Health"},{"key":"10.1016\/j.pupt.2004.08.001_bib70","first-page":"201","article-title":"[Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors] Regulacion del tono bronquial en la enfermedad pulmonar obstructiva cronica (EPOC): papel de los receptores muscarinicos","volume":"20","author":"Abad","year":"2003","journal-title":"An Med Int"},{"key":"10.1016\/j.pupt.2004.08.001_bib71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0163-7258(03)00004-4","article-title":"Muscarinic acetylcholine receptors and airway diseases","volume":"98","author":"Coulson","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pupt.2004.08.001_bib72","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/thx.49.6.545","article-title":"Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis","volume":"49","author":"Tamaoki","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2004.08.001_bib73","first-page":"304","article-title":"Drug effects on mucociliary function","volume":"128","author":"Pavia","year":"1983","journal-title":"Eur J Respir Dis Suppl"},{"key":"10.1016\/j.pupt.2004.08.001_bib74","first-page":"P1678","article-title":"Effect of inhaled tiotropium on tracheobronchial clearance in patients with COPD","volume":"18","author":"Hasani","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib75","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1165\/ajrcmb.12.2.7865217","article-title":"Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells","volume":"12","author":"Levine","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pupt.2004.08.001_bib76","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1471-4892(01)00045-5","article-title":"The role of epidermal growth factor in mucus production","volume":"1","author":"Nadel","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pupt.2004.08.001_bib77","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543784.10.7.1361","article-title":"Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease","volume":"10","author":"Giembycz","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pupt.2004.08.001_bib78","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200212-1490OC","article-title":"Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease","volume":"168","author":"Gamble","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib79","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1749-6632.2003.tb03152.x","article-title":"The role of neural inflammation in asthma and chronic obstructive pulmonary disease","volume":"992","author":"Joos","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pupt.2004.08.001_bib80","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1517\/13543776.11.7.1097","article-title":"Tachykinin receptor antagonists for asthma and COPD","volume":"11","author":"Rogers","year":"2001","journal-title":"Expert Opin Ther Patents"},{"key":"10.1016\/j.pupt.2004.08.001_bib81","doi-asserted-by":"crossref","first-page":"40982","DOI":"10.1074\/jbc.M105614200","article-title":"MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro","volume":"276","author":"Li","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pupt.2004.08.001_bib82","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nm983","article-title":"A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma","volume":"10","author":"Singer","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.pupt.2004.08.001_bib83","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1183\/09031936.04.00096504","article-title":"Expression of HCLCA1 in cystic fibrosis lungs is associated with mucus overproduction","volume":"23","author":"Hauber","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2004.08.001_bib84","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/0470860790.ch10","article-title":"A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction","volume":"248","author":"Zhou","year":"2002","journal-title":"Novartis Found Symp"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553904000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553904000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T23:29:59Z","timestamp":1549150199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553904000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S1094553904000641"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2004.08.001","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}